Michael Nuoqing Yi
Directeur en chef des Investissements chez Hillhouse Investment Management Ltd. (Invest)
Profil
Michael Nuoqing Yi has worked as a Director at Sironax Ltd.
and as a Co-Chief Investment Officer at Hillhouse Investment Management Ltd.
(Invest).
Postes actifs de Michael Nuoqing Yi
Sociétés | Poste | Début |
---|---|---|
Hillhouse Investment Management Ltd. (Invest)
Hillhouse Investment Management Ltd. (Invest) Investment ManagersFinance Hillhouse Capital Management Ltd. (Hillhouse Capital) is a Private Equity/Venture Capital firm, a subsidiary of Hillhouse Capital Group Ltd. founded in 2005 by Lei Zhang. The firm is headquartered in Hong Kong. | Directeur en chef des Investissements | - |
Sironax Ltd.
Sironax Ltd. Pharmaceuticals: MajorHealth Technology Sironax Ltd. is a clinical-stage biotechnology company located in Beijing, China. The Chinese company is dedicated to discovering and developing novel treatments for patients with age-related degenerative diseases. Sironax has built a diverse pipeline of multiple programs, focusing on key mechanisms underlying age-related degenerative diseases including regulated cell death, neuroprotective pathways, and neuroinflammation. Currently, Sironax is conducting early clinical studies with sir0365 and sir2446, in addition to ongoing preclinical research. | Directeur/Membre du Conseil | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Entreprise privées | 2 |
---|---|
Hillhouse Investment Management Ltd. (Invest)
Hillhouse Investment Management Ltd. (Invest) Investment ManagersFinance Hillhouse Capital Management Ltd. (Hillhouse Capital) is a Private Equity/Venture Capital firm, a subsidiary of Hillhouse Capital Group Ltd. founded in 2005 by Lei Zhang. The firm is headquartered in Hong Kong. | Finance |
Sironax Ltd.
Sironax Ltd. Pharmaceuticals: MajorHealth Technology Sironax Ltd. is a clinical-stage biotechnology company located in Beijing, China. The Chinese company is dedicated to discovering and developing novel treatments for patients with age-related degenerative diseases. Sironax has built a diverse pipeline of multiple programs, focusing on key mechanisms underlying age-related degenerative diseases including regulated cell death, neuroprotective pathways, and neuroinflammation. Currently, Sironax is conducting early clinical studies with sir0365 and sir2446, in addition to ongoing preclinical research. | Health Technology |